May 15, 2025

Men With Broken Heart Syndrome Have Twice the Mortality Risk: Study

A large U.S. study of nearly 200,000 Takotsubo cardiomyopathy cases found persistently high mortality—especially among men—despite rising incidence and increased recognition from 2016 to 2020.

Conexiant

May 15, 2025

Chikungunya Vaccine Linked to Adverse Events

The FDA and CDC have paused use of the Ixchiq chikungunya vaccine in adults aged 60 and older due to reports of serious postmarketing adverse events.

Conexiant

May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 08, 2025

SGLT2 Inhibitors Lower Hyperkalemia Risk in Patients Taking RAASi 

Researchers found that starting SGLT2 inhibitors in older patients on RAAS inhibitors reduced the risk of hyperkalemia and helped more patients stay on RAAS therapy.

Conexiant

May 07, 2025

Aspirin Discontinuation Could Fail to Lower cSDH Recurrence

In a multicenter randomized trial, discontinuing aspirin for 12 days during subdural hematoma surgery did not lower recurrence rates or reduce bleeding compared to continuing the drug.

Conexiant

May 01, 2025

Modifiable Risk Factors Linked to Sudden Cardiac Arrest Incidence

A UK Biobank analysis identified 56 modifiable risk factors for sudden cardiac arrest; lifestyle improvements alone could prevent up to 18% of cases, with a total prevention potential of 63%.

Conexiant

April 28, 2025

Brisk Walking Linked to Reduced Arrhythmia Risk Study

Faster walking pace was associated with a decreased risk of cardiac arrhythmias, researchers wrote in the UK Biobank study.

Conexiant

April 25, 2025

Multidimensional Sleep Health Affects Heart

Sleep is not a unitary physiologic experience, the AHA states in its new scientific statement, which redefines how physicians should assess sleep’s impact on cardiometabolic health.

Conexiant

April 24, 2025

Large Trial Finds No Stroke Benefit From CEP, Study

A large U.K. trial found that routine use of cerebral embolic protection did not decrease the incidence of stroke within 72 hours among patients undergoing TAVI.

Conexiant